Characteristic MicroRNA Expression Induced by δ-Opioid Receptor Activation in the Rat Liver Under Prolonged Hypoxia

Feng Zhi1,2, Naiyuan Shao1, Lian Xue2

  • 1Department of Neurosurgery, The First People's Hospital of Changzhou, Changzhou, China.

Abstract

Insights

Hypoxia alters liver microRNA (miRNA) profiles. Activating the delta-opioid receptor (DOR) can modify these hypoxia-induced changes, suggesting a potential therapeutic strategy for liver injury.

Area of Science:

  • Hepatology
  • Molecular Biology
  • Pharmacology

Background:

  • Hypoxic/ischemic liver injury presents a significant clinical challenge with limited treatment options.
  • MicroRNAs (miRNAs) play a role in hypoxic/ischemic events.
  • Delta-opioid receptor (DOR) activation is known to be protective against hypoxic/ischemic injury.

Purpose of the Study:

  • To investigate the effect of delta-opioid receptor (DOR) activation on hepatic miRNA expression under hypoxic conditions.
  • To determine if pharmacological activation of DOR can modulate miRNA expression during hypoxia in the liver.
  • To explore potential therapeutic strategies for hypoxic liver injury by targeting DOR and miRNA pathways.

Main Methods:

  • Male Sprague Dawley rats were subjected to hypoxia (9.5-10% O2) for 1, 5, or 10 days.
  • DOR activation was administered with or without hypoxia exposure.
  • miRNA expression was analyzed using TaqMan low-density array (TLDA) and quantitative real-time PCR.

Main Results:

  • One-day hypoxia upregulated 9 miRNAs and downregulated 2 miRNAs.
  • Prolonged hypoxia (5 and 10 days) altered the expression of 4 specific miRNAs.
  • DOR activation alone shifted the expression of 8 miRNAs in normoxic conditions.
  • DOR activation modulated hypoxia-induced changes in 6 key miRNAs.

Conclusions:

  • Hypoxia significantly alters the miRNA expression profile in the liver.
  • DOR activation demonstrates the capacity to modify hypoxia-induced changes in hepatic miRNA expression.
  • Targeting DOR pharmacotherapy presents a potential avenue for altering hypoxic/ischemic pathophysiology in the liver.